EUCTR2016-001779-54-ES进行中（未招募）1 期
A multicenter phase II trial to evaluate the efficacy and safety ofpembrolizumab and gemcitabine in patients with HER2-negative Advanced Breast Cancer (ABC). PANGEA-Breast” - PANGEA-Breast
GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)0 个研究点目标入组 36 人开始时间: 2016年11月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. The patient has signed and dated the informed consent document and it has been obtained before conducting any procedure specifically for the study.
- •2. Female = 18 years of age on day of signing informed consent.
- •3. Histological/cytological confirmation of breast cancer with evidence of advanced disease, not amenable to resection or radiation therapy with curative intent.
- •4. Documented luminal A, luminal B (HER2-negative) or triple negative disease by
- •immunohistochemistry (IHQ) and/or in situ hybridization (FISH/CISH/SISH) based on
- •local testing on the most recent tumour biopsy defined as follows:
- •o Luminal A: tumour with positive oestrogen receptor (ER) status (>1% of tumour cells with ER expression) and HER2-negative status (IHQ score 0/1+ or negative by in situ hybridization defined as a HER2/CEP17 ratio < 2 or for single probe assessment a HER2 copy number < 4) and high progesterone receptor (PgR) (> 20% of tumour cells with PgR expression) and low Ki67 (< 14%).
- •o Luminal B (HER2-negative): tumour with positive ER status (>1% of tumour cells with ER expression) and HER2-negative status (IHQ score 0/1+ or negative by in situ hybridization defined as a HER2/CEP17 ratio < 2 or for single probe assessment a HER2 copy number < 4) and either low or negative PgR (< 20% of tumour cells with PgR expression) and/or high Ki67 (= 14%).
- •o Triple negative: tumour with negative hormone receptor status (<1% of tumour
- •cells with ER and PgR expression) and HER2-negative status (IHQ score 0/1+ or negative by in situ hybridization defined as a HER2/CEP17 ratio < 2 or for single probe assessment a HER2 copy number < 4).
- •5. Have at least one unidimensionally measurable lesion by RECIST 1.1.
- •6. Have a performance status of 0, 1 or 2 on the Eastern Cooperative Oncology Group
- •(ECOG) Performance Scale.
- •7. Demonstrate adequate organ function as follows (all screening labs should be performed within 7 days of study treatment initiation):
- •o Bone marrow:
- •Absolute Neutrophil Count (ANC) = 1,500/mm3 (1.5x109/l)
- •Platelets = 100,000/mm3 (100x109/l)
- •Hemoglobin = 9g/dl or = 5.6 mmol/l without transfusion or EPO dependency (within 7 days of assessment)
- •Serum total bilirubin = 1.5 x Upper Limit of Normal (ULN)
- •Alkaline Phosphatase = 2.5 x ULN
- •AST (SGOT) and ALT (SGPT) = 2.5 x ULN or = 5 x ULN for patients with liver metastases
- •Albumin = 2.5 g/dl
- •Serum creatinine = 1.5 x ULN or creatinine clearance = 60 ml/min for patients with creatinine levels > 1.5 x ULN
- •o Coagulation:
- •International Normalized Ratio (INR) or Prothrombin Time (PT) = 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants.
- •Activated Partial Thromboplastin Time (aPTT) = 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants.
- •8. Prior treatment with anthracyclines and taxanes (unless clinically contraindicated) and two or more prior lines of hormone therapy in hormone receptor positive disease.
- •9. At least 3 months life expectancy.
- •10. Patient of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study drug/medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •11. Patients of childbearing potential (see section 4.4. for definition) must be willing to use an adequate method of
排除标准
- •1. HER2-positive disease by immunohistochemistry or in situ hybridation (FISH-SISHCISH).
- •2. Patient is currently participating or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drug/medication.
- •3. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., = grade 1 or at baseline) from adverse events due to
- •agents administered more than 4 weeks earlier.
- •4. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., = grade 1 or at baseline) from adverse events due to a previously administered agent.
- •o Note: Patients with = grade 2 neuropathy are an exception to this criterion and may
- •qualify for the study.
- •o Note: If patient received major surgery, they must have recovered adequately from
- •the toxicity and/or complications from the intervention prior to starting therapy.
- •5. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
- •6. Has received a live vaccine within 30 days of planned start of study therapy.
- •o Note: Seasonal influenza vaccines for injection are generally inactivated flu
- •vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist®)
- •are live attenuated vaccines, and are not allowed.
- •7. Has hypersensitivity to pembrolizumab, gemcitabine or any of theirs excipients.
- •8. Has known active central nervous system (CNS) metastases and/or carcinomatous
- •meningitis. Patients with previously treated brain metastases may participate provided
- •they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and all neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
- •9. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study
- •drug/medication.
- •10. Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- •11. Has a current or prior malignancy within the previous 5 years (other than breast cancer or adequately treated basal cell or squamous cell carcinoma of the skin or in-situ carcinoma of the cervix).
- •12. Has a history of (non-infectious) pneumonitis that required steroids or current
- •pneumonitis.
- •13. Has an active infection requiring systemic therapy.
- •14. Has a known history of active TB (Bacillus Tuberculosis) or Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies) or a known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
- •15. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient’s participation for the full duration of the trial, or is not in the best interest of the
研究者
相似试验
已完成
不适用
The efficacy of epirubicin, cisplatin and capecitabine in carcinomas of unknown primary origin (CUP): prospective validation of diagnosis, classfication and metabolic responsesCarcinoma of unknown primary origin (CUP)CancerISRCTN17282276HS Greater Glasgow and Clyde (UK)59
尚未招募
2 期
Multicenter phase II trial to evaluate the efficacy of Abound (nutrition product including HMB, arginine, and glutamine) on the clinical course of anastomotic leakage after gastrectomy in patients with gastric cancerAnastomotic leakage after gastrectomy for gastric cancerJPRN-UMIN000028945agoya University20
招募中
2 期
A multicenter phase II study to evaluate the efficacy and safety of fixed-duration sequential treatment combined with novel agents and autologous stem cell transplantation for newly diagnosed elderly multiple myeloma. -JSCT EMM21Multiple myelomaJPRN-jRCTs071210084Kikushige Yoshikane75
已完成
2 期
A multicenter phase II trial of the efficacy and safety of tadalafil with pre-eclampsia.pregnancy induced hypertensionJPRN-UMIN000024042Mie university hospital, Department of Obstetrics and Gynecology160
已完成
2 期
A multicenter phase II trial of the efficacy and safety of tadalafil in fetus with early-onset growth restriction.Fetal growth restrictionJPRN-UMIN000023778Mie university hospital, Department of Obstetrics and Gynecology140